TREX1 Inhibitor Assays May Aid the Discovery Novel HIV Treatments
Monday, 17 May 2021
TREX1 Inhibitor assays could help move things forward for cancer and HIV treatments. – The immune system of humans is remarkable. Unlike the adaptive immune response, the innate immune response is quick and is considered the first line of defense against pathogens and foreign DNA. This foreign material can come from pathogens, tumor cells, or
- Published in Company, Emerging Targets
No Comments
BellBrook Labs Receives NIH Funding for Novel Approach to Stimulating Antitumor Immunity
Tuesday, 09 March 2021
The National Cancer Institute (NCI) recently awarded BellBrook Labs a $300,000 Phase I Small Business Innovative Research (SBIR) grant to develop tools for discovering small-molecule antagonists of TREX1, a checkpoint at the top of the critical immunostimulatory STING pathway. Madison, WI – March 2021 – BellBrook Labs has been awarded a $300,000 Phase I Small